Drugs / EG-007
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05106127 | Aug 2026 → Mar 2027 expected | endometrial cancer | Evergreen Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05077215 | Dec 2026 → Dec 2027 expected | endometrial cancer | Evergreen Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EG-007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05106127 ↗ |